Enrollment in Affordable Care Act marketplace plans has reached record levels, and the Biden administration is using those numbers to push for continuation of enhanced subsidies that have lowered premiums for the plans.
Enrollment in Affordable Care Act (ACA) marketplace plans has reached record levels, and the Biden administration is using those numbers to push for continuation of enhanced subsidies that have lowered premiums for the plans.
CMS announced in March 2022 on the 12th anniversary of the healthcare reform law that enrollment had reached 14.5 million, a 21% increase over last year. About 10 million people enrolled through the federal government’s exchange, Healthcare.gov and the rest through the exchanges that 18 states have set up on their own. Some of the enrollment deadlines for those state-based exchanges are later than the Jan. 15 deadline for Healthcare.gov, so the final tally for the number of Americans in ACA marketplaces is likely to increase.
As a candidate, President Joe Biden said he would build on the ACA rather than push for Medicare for all. The administration has framed the enrollment figures as validation of that approach.
Katie Keith, J.D., M.P.H., an ACA expert who holds positions at the Georgetown University Law Center in Washington, D.C., and writes about the law for Health Affairs,
noted in a blog post for the journal that enrollment was especially strong in several states that have not expanded their Medicaid programs under the ACA, including Florida, Georgia, North Carolina and Texas.
Keith and the administration pointed to increased subsidies as one of the main reasons for the increased enrollment. About one-third of the people who signed up through Healthcare.gov for coverage selected a plan with a monthly premium of $10 or less. The Biden administration wants the enhanced subsidies to continue and estimates that 3.4 million people will lose coverage through the marketplace plans if they aren’t.
The administration has issued new rules that will apply to the 2023 coverage year. Keith said changes include requirements that seek to standardize benefit design and raise network adequacy standards.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More